Table 3.
Treatment-emergent AEs regardless of attribution (N = 51)
| Adverse Event | All grades* >15%, n (%) | Grades ≥3, n (%) |
|---|---|---|
| Patients reporting ≥1 AE | 51 (100) | 46 (90) |
| Fatigue | 20 (39) | 4 (8) |
| Nausea | 20 (39) | 0 |
| Constipation | 18 (35) | 0 |
| Febrile neutropenia | 18 (35) | 17 (33) |
| Hypokalemia | 16 (31) | 4 (8) |
| Hypocalcaemia | 15 (29) | 7 (14) |
| Edema peripheral | 13 (25) | 0 |
| Vomiting | 13 (25) | 0 |
| Hypomagnesaemia | 12 (24) | 0 |
| Diarrhea | 11 (22) | 0 |
| Leukocytosis | 11 (22) | 10 (20) |
| Cough | 11 (22) | 0 |
| Dyspnea | 11 (22) | 2 (4) |
| Pyrexia | 10 (20) | 1 (2) |
| Abdominal pain | 10 (20) | 2 (4) |
| Anemia | 10 (20) | 8 (16) |
| Mucosal inflammation | 9 (18) | 2 (4) |
| Pneumonia | 9 (18) | 7 (14) |
*
Graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.